Back to top
more

QuidelOrtho (QDEL)

(Real Time Quote from BATS)

$23.81 USD

23.81
1,461,280

+0.13 (0.55%)

Updated Aug 6, 2025 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Phibro Animal Health (PAHC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of 28.57% and 3.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues

by Zacks Equity Research

QDEL's preliminary fourth-quarter revenues align with the company's expectations.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.

Zacks Equity Research

QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.

Zacks Equity Research

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 174.19% and 12.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL's strong product portfolio raises optimism about the stock.

Zacks Equity Research

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

by Zacks Equity Research

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

Zacks Equity Research

QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

by Zacks Equity Research

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 66.67% and 3.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?

by Zacks Equity Research

National Vision (EYE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?

by Zacks Equity Research

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

Zacks Equity Research

Here's What Key Metrics Tell Us About QuidelOrtho (QDEL) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for QuidelOrtho (QDEL) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 2.33% and 1.96%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing

by Zacks Equity Research

QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.